


Gp 1627



Attorney Docket No.: 5655.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5
HKO
2-9-00

In re Application of: Pedersen et al.

Serial No.: 09/390,851

Group Art Unit: To be assigned

Filed: September 7, 1999

Examiner: To be assigned

RECEIVED

FEB 07 2000

For: Enzyme Activity Screen With Direct Substrate Reloading

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Information Disclosure Statement
2. PTO-1449 Form
3. Copy of References


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks
Washington, DC 20231

on January 31, 2000.

Gina Maldonado
(name of person mailing paper)


(signature of person mailing paper)



Attorney Docket No.: 5655.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pedersen et al.

Application No.: 09/390,851

Group Art Unit: To be assigned

Filed: September 7, 1999

Examiner: To be assigned

For: Enzyme Activity Screen With Direct Substrate Reloading

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. U.S. Patent No. 5,571,681
2. WO 97/47314
3. Avalle et al., (1997) Bioorganic & Medicinal Letters 7(4):479-484
4. Eichler et al., (1993) Biochemistry 32:11035-11041
5. Evans et al., (1996) Nature Biotechnology 14:504-507

6. Dialog Information Services, Medline Accession No. 1998294385
7. Dialog Information Services, Dialog Accession No. 94032215
8. STN International, Caplus Accession No. 165868

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: January 31, 2000



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123